TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Additional Exercise Therapy in Patients With Peripheral Arterial Disease: The Value of Supervised Exercise Therapy After Invasive Treatment of Peripheral Arterial Disease.
Brief Summary: The objective of this study is to investigate what the value is of SET after a radiological or surgical intervention for peripheral arterial disease in the aorto-iliacal, femoro-popliteal and crural segments in comparison with a control group.


Options:
A: Arm Label: INVASIVE (INV) group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: INVASIVE (INV) treatment, Other: Best medical treatment (BMT) | Arm Label: NON-INVASIVE (NON) group; Type: ACTIVE_COMPARATOR; Interventions: Other: Best medical treatment (BMT) | Intervention Type: PROCEDURE; Name: INVASIVE (INV) treatment; Assigned to Arm(s): INVASIVE (INV) group | Intervention Type: OTHER; Name: Best medical treatment (BMT); Assigned to Arm(s): INVASIVE (INV) group, NON-INVASIVE (NON) group
B: Arm Label: Angioplasty / surgery and exercise therapy; Type: EXPERIMENTAL; Interventions: Procedure: Angioplasty / surgery and exercise therapy | Arm Label: Angioplasty / surgery; Type: NO_INTERVENTION; Interventions: Procedure: angioplasty / surgery | Intervention Type: PROCEDURE; Name: angioplasty / surgery; Assigned to Arm(s): Angioplasty / surgery | Intervention Type: PROCEDURE; Name: Angioplasty / surgery and exercise therapy; Assigned to Arm(s): Angioplasty / surgery and exercise therapy
C: Arm Label: PTA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous Transluminal Angioplasty (PTA) | Arm Label: SEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Supervised Exercise Programme (SEP) | Arm Label: PTA+SEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Combined Treatment | Intervention Type: PROCEDURE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): PTA | Intervention Type: PROCEDURE; Name: Supervised Exercise Programme (SEP); Assigned to Arm(s): SEP | Intervention Type: PROCEDURE; Name: Combined Treatment; Assigned to Arm(s): PTA+SEP
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Therapy, Drug: Cilostazol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Drug: Cilostazol | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Behavioral: Supervised Exercise Therapy | Intervention Type: DEVICE; Name: Stent; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Therapy; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Additional Exercise Therapy in Patients With Peripheral Arterial Disease: The Value of Supervised Exercise Therapy After Invasive Treatment of Peripheral Arterial Disease.
Brief Summary: The objective of this study is to investigate what the value is of SET after a radiological or surgical intervention for peripheral arterial disease in the aorto-iliacal, femoro-popliteal and crural segments in comparison with a control group.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Self-managed walking | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Self-managed walking; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 2
C: Arm Label: Angioplasty / surgery and exercise therapy; Type: EXPERIMENTAL; Interventions: Procedure: Angioplasty / surgery and exercise therapy | Arm Label: Angioplasty / surgery; Type: NO_INTERVENTION; Interventions: Procedure: angioplasty / surgery | Intervention Type: PROCEDURE; Name: angioplasty / surgery; Assigned to Arm(s): Angioplasty / surgery | Intervention Type: PROCEDURE; Name: Angioplasty / surgery and exercise therapy; Assigned to Arm(s): Angioplasty / surgery and exercise therapy
D: Arm Label: PTA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous Transluminal Angioplasty (PTA) | Arm Label: SEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Supervised Exercise Programme (SEP) | Arm Label: PTA+SEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Combined Treatment | Intervention Type: PROCEDURE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): PTA | Intervention Type: PROCEDURE; Name: Supervised Exercise Programme (SEP); Assigned to Arm(s): SEP | Intervention Type: PROCEDURE; Name: Combined Treatment; Assigned to Arm(s): PTA+SEP

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Blind, Multinational, Multicentre, Parallel-group, Placebo-controlled Design Trial of the Efficacy and Safety of Nebulised Beclometahsone Dipropionate (400 μg b.i.d.) Plus as Needed Salbutamol Versus as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination, in the 12-week Treatment of Young Children With Asthma Symptoms
Brief Summary: To demonstrate a superior efficacy of BDP plus rescue salbutamol suspension for nebulisation, compared to placebo plus rescue salbutamol, in the relief of symptoms of asthma in young children with persistent symptoms of asthma.


Options:
A: Intervention Type: DRUG; Name: Pulmicort (budesonide) pMDI; Assigned to Arm(s): N/A
B: Arm Label: Placebo Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide, Drug: Placebo Budesonide | Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide, Drug: Placebo Budesonide | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide, Placebo Budesonide | Intervention Type: DRUG; Name: Placebo Budesonide; Assigned to Arm(s): Budesonide, Placebo Budesonide
C: Intervention Type: DRUG; Name: beclomethasone/salbutamol combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beclomethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: salbutamol; Assigned to Arm(s): N/A
D: Arm Label: Beclomethasone dipropionate; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate | Arm Label: Beclomethasone dipropionate/Salbutamol combination; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate/Salbutamol combination | Arm Label: Salbutamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salbutamol | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Beclomethasone dipropionate | Intervention Type: DRUG; Name: Beclomethasone dipropionate/Salbutamol combination; Assigned to Arm(s): Beclomethasone dipropionate/Salbutamol combination | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Salbutamol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exploratory Study to Investigate the Efficacy and Safety of Recombinant Growth Hormone as Add-on Treatment in Patients With Severe Fibromialgia
Brief Summary: There are evidences of functional growth hormone (GH) deficiency, expressed by means of low serum levels of insulin-like growth factor 1 (IGF-1), in a subset of fibromyalgia patients. The efficacy of low GH doses versus placebo has been demonstrated in this population. We assessed the efficacy and safety of GH added to standard therapy compared to standard therapy alone in the treatment of severe, prolonged and well-treated fibromialgya patients with low IGF-1 levels.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4
B: Intervention Type: DRUG; Name: sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amitriptyline, fluoxetine and tramadol alone (control group); Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D
D: Arm Label: one arm study; Type: EXPERIMENTAL; Interventions: Drug: trazodone, pregabalin | Intervention Type: DRUG; Name: trazodone, pregabalin; Assigned to Arm(s): one arm study

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exploratory Study to Investigate the Efficacy and Safety of Recombinant Growth Hormone as Add-on Treatment in Patients With Severe Fibromialgia
Brief Summary: There are evidences of functional growth hormone (GH) deficiency, expressed by means of low serum levels of insulin-like growth factor 1 (IGF-1), in a subset of fibromyalgia patients. The efficacy of low GH doses versus placebo has been demonstrated in this population. We assessed the efficacy and safety of GH added to standard therapy compared to standard therapy alone in the treatment of severe, prolonged and well-treated fibromialgya patients with low IGF-1 levels.


Options:
A: Arm Label: water-based exercise intervention; Type: EXPERIMENTAL; Interventions: Behavioral: water-based exercise | Arm Label: land-based exercise intervention; Type: EXPERIMENTAL; Interventions: Behavioral: land-based exercise intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: water-based exercise; Assigned to Arm(s): water-based exercise intervention | Intervention Type: BEHAVIORAL; Name: land-based exercise intervention; Assigned to Arm(s): land-based exercise intervention
B: Intervention Type: BEHAVIORAL; Name: walking program, resistance muscular exercise; Assigned to Arm(s): N/A
C: Arm Label: CFQ Qigong training group; Type: ACTIVE_COMPARATOR; Interventions: Other: CFQ Qigong | Intervention Type: OTHER; Name: CFQ Qigong; Assigned to Arm(s): CFQ Qigong training group
D: Intervention Type: DRUG; Name: sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amitriptyline, fluoxetine and tramadol alone (control group); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Targeted Pharmacologic Interventions for Autism: A Double-Blind, Placebo-Controlled Trial of Atomoxetine in Children and Adolescents With Autism
Brief Summary: This study will evaluate the effectiveness of atomoxetine in treating children with attention deficit hyperactivity disorder symptoms associated with autistic disorder, Asperger's syndrome, and pervasive developmental disorder, not otherwise specified.


Options:
A: Arm Label: Atomoxetine; Type: EXPERIMENTAL; Interventions: Drug: Atomoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): Atomoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Cannabinoids - 99% pure cannabinoids mix; Type: EXPERIMENTAL; Interventions: Drug: Cannabinoids - 99% pure cannabinoids mix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cannabinoids - whole plant extract; Type: EXPERIMENTAL; Interventions: Drug: Cannabinoids - whole plant extract | Intervention Type: DRUG; Name: Cannabinoids - 99% pure cannabinoids mix; Assigned to Arm(s): Cannabinoids - 99% pure cannabinoids mix | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Cannabinoids - whole plant extract; Assigned to Arm(s): Cannabinoids - whole plant extract
D: Arm Label: Placebo for AChEI and Choline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Indistinguishable placebo tablets, matching both donepezil and choline | Arm Label: AChEI and Choline; Type: EXPERIMENTAL; Interventions: Drug: Acetyl-Choline Esterase Inhibitors and Choline supplements | Intervention Type: DRUG; Name: Acetyl-Choline Esterase Inhibitors and Choline supplements; Assigned to Arm(s): AChEI and Choline | Intervention Type: DRUG; Name: Indistinguishable placebo tablets, matching both donepezil and choline; Assigned to Arm(s): Placebo for AChEI and Choline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Targeted Pharmacologic Interventions for Autism: A Double-Blind, Placebo-Controlled Trial of Atomoxetine in Children and Adolescents With Autism
Brief Summary: This study will evaluate the effectiveness of atomoxetine in treating children with attention deficit hyperactivity disorder symptoms associated with autistic disorder, Asperger's syndrome, and pervasive developmental disorder, not otherwise specified.


Options:
A: Arm Label: Atomoxetine; Type: EXPERIMENTAL; Interventions: Drug: Atomoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): Atomoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: MPH Trial-Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: MPH Trial: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: Med Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Intervention Type: DRUG; Name: Methylphenidate-extended release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: DRUG; Name: Methylphenidate-immediate release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): MPH Trial-Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Targeted Pharmacologic Interventions for Autism: A Double-Blind, Placebo-Controlled Trial of Atomoxetine in Children and Adolescents With Autism
Brief Summary: This study will evaluate the effectiveness of atomoxetine in treating children with attention deficit hyperactivity disorder symptoms associated with autistic disorder, Asperger's syndrome, and pervasive developmental disorder, not otherwise specified.


Options:
A: Arm Label: Atomoxetine; Type: EXPERIMENTAL; Interventions: Drug: Atomoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): Atomoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arbaclofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arbaclofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Arbaclofen; Assigned to Arm(s): Arbaclofen | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: secretin, synthetic porcine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: secretin, biologically derived porcine; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RG7314; Type: EXPERIMENTAL; Interventions: Drug: RG7314 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RG7314; Assigned to Arm(s): RG7314

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer (With Local Progression or Metastasis)
Brief Summary: In patients with unresectable advanced pancreatic cancer, non-inferiority of TS-1 monotherapy and superiority of GEM + TS-1 combination therapy to gemcitabine (GEM) will be verified using survival time.


Options:
A: Arm Label: GSK1120212 plus Gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: GSK1120212, Drug: Gemcitabine | Arm Label: Placebo plus Gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Placebo | Intervention Type: DRUG; Name: GSK1120212; Assigned to Arm(s): GSK1120212 plus Gemcitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): GSK1120212 plus Gemcitabine, Placebo plus Gemcitabine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus Gemcitabine
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine plus TS-1 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: TS-1 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine | Intervention Type: DRUG; Name: Gemcitabine plus TS-1; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: TS-1; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): 3
C: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Erlotinib | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Erlotinib | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm A, Arm B
D: Arm Label: A; Type: NO_INTERVENTION; Interventions: Genetic: cetuximab | Intervention Type: GENETIC; Name: cetuximab; Assigned to Arm(s): A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Physical Exercise on Decrease of Pain in Patients With Fibromyalgia:Randomized Clinical Trial
Brief Summary: Fibromyalgia (FMS) is a syndrome expressed by chronic widespread body pain which leads to reduced physical function and frequent use of health care services. Exercise training is commonly recommended as a treatment.

The purpose of this study is to determine whether a supervised resistance muscular exercise (RME) and walking program (WP) are effective in the treatment of FMS on decrease of pain.

The practical of the RME reduces the pain of participants with FMS.


Options:
A: Arm Label: placebo (P); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: phototherapy (FT); Type: EXPERIMENTAL; Interventions: Radiation: Group Phototherapy | Arm Label: phototherapy+Physical activity (FT+A); Type: EXPERIMENTAL; Interventions: Radiation: Phototherapy + Physical activity | Arm Label: Physical activity (A); Type: EXPERIMENTAL; Interventions: Other: Physical activity | Intervention Type: RADIATION; Name: Group Phototherapy; Assigned to Arm(s): phototherapy (FT) | Intervention Type: RADIATION; Name: Phototherapy + Physical activity; Assigned to Arm(s): phototherapy+Physical activity (FT+A) | Intervention Type: OTHER; Name: Physical activity; Assigned to Arm(s): Physical activity (A) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo (P)
B: Intervention Type: BEHAVIORAL; Name: walking program, resistance muscular exercise; Assigned to Arm(s): N/A
C: Arm Label: water-based exercise intervention; Type: EXPERIMENTAL; Interventions: Behavioral: water-based exercise | Arm Label: land-based exercise intervention; Type: EXPERIMENTAL; Interventions: Behavioral: land-based exercise intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: water-based exercise; Assigned to Arm(s): water-based exercise intervention | Intervention Type: BEHAVIORAL; Name: land-based exercise intervention; Assigned to Arm(s): land-based exercise intervention
D: Intervention Type: BEHAVIORAL; Name: cognitive-behavioral therapy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Physical Exercise on Decrease of Pain in Patients With Fibromyalgia:Randomized Clinical Trial
Brief Summary: Fibromyalgia (FMS) is a syndrome expressed by chronic widespread body pain which leads to reduced physical function and frequent use of health care services. Exercise training is commonly recommended as a treatment.

The purpose of this study is to determine whether a supervised resistance muscular exercise (RME) and walking program (WP) are effective in the treatment of FMS on decrease of pain.

The practical of the RME reduces the pain of participants with FMS.


Options:
A: Arm Label: Group education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group education | Arm Label: 8-form Yang-style Tai chi program; Type: EXPERIMENTAL; Interventions: Behavioral: 8-form Yang-style Tai chi | Intervention Type: BEHAVIORAL; Name: 8-form Yang-style Tai chi; Assigned to Arm(s): 8-form Yang-style Tai chi program | Intervention Type: BEHAVIORAL; Name: Group education; Assigned to Arm(s): Group education
B: Intervention Type: BEHAVIORAL; Name: cognitive-behavioral therapy; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: self-management program; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: walking program, resistance muscular exercise; Assigned to Arm(s): N/A

Answer: D